A view on new drugs for macular degeneration.

A view on new drugs for macular degeneration. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A view on new drugs for macular degeneration. Abstract Text:

,

Estimates suggest that in Europe 2.3% of people older than 65 years have neovascular age-related macular degeneration, which can lead to loss of central vision. The condition is the leading cause of blindness in the estern world, and the third commonest worldwide. It is characterised by growth of new blood vessels beneath the retina (choroidal neovascularisation), a process stimulated by the secretion of vascular endothelial growth factor (VEGF).3 Two new drugs, pegaptanib sodium (Macugen - Pfizer) and ranibizumab (Lucentis -Novartis), that block the effects of VEGF are now licensed in the UK for patients with neovascular age-related macular degeneration. A third drug that inhibits VEGF activity, bevacizumab (Avastin - Roche), is also used for this condition but is licensed only for metastatic colorectal or breast cancer. Here we consider the role of pegaptanib, ranibizumab and bevacizumab in patients with neovascular age-related macular degeneration.

A view on new drugs for macular degeneration. Publishing Authors By Initials

,

For similar eye diseases: retinal diseases: retinal degeneration: macular degeneration research abstracts see: eye diseases: retinal diseases: retinal degeneration: macular degeneration research

PUBMED ID PMID:

MEDLINE DATE:

A view on new drugs for macular degeneration. Journal Published:

PUBLICATION TYPE: Review

Journal: Drug and therapeutics bulletin

VOLUME: 45

Page Numbers: 49-52

Journal Abbreviation:

ISSN: 0012-6543

DAY: 21

MONTH: Jul

YEAR: 2007

A view on new drugs for macular degeneration. Information

Number of References: 26

LANGUAGE: eng

NlmUniqueID: 112037

A view on new drugs for macular degeneration. Keywords Mesh Terms:

KEYWORDS: Macular Degeneration

MESH TERMS: drug therapy

Chemical & Substance for Abstract: A view on new drugs for macular degeneration. Information

Substance Name: ranibizumab

Registry Number: 0

Grant and Affiliation Information for A view on new drugs for macular degeneration.

AFFILIATION:

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Drug Ther Bull

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A view on new drugs for macular degeneration Related Publications